172 completed. 172 Phase 2, 33 Phase 1, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 172 | Completed 172 |
| Phase 1 | 33 | Completed 33 |
| Phase 3 | 5 | Completed 5 |
Follow Otorhinolaryngologic Neoplasms: new trials by email Literature Review of Otorhinolaryngologic Neoplasms trials Research Report on Otorhinolaryngologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pre-Radiotherapy n-6/n-3 Fatty Acid Ratio Predicts Severe Oral Mucositis in Nasopharyngeal Carcinoma Toripalimab (240mg day1, Q3W*3cycle), Cisplatin (80 mg/m2), Nab-paclitaxel - Nasopharyngeal Carcinoma (NPC), Radiation-induced Oral Mucositis | Phase 2 | Completed | Affiliated Hospital of Guangdong Medical University | 210 | 2024-11-01 | 2026-11-05 |
| Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent RVP-001 - Central Nervous System (CNS) Lesions, Brain Metastases | Phase 2 | Completed | Reveal Pharmaceuticals Inc. | 18 | 2024-08-15 | 2025-12-26 |
| A Lithium-containing Mouthwash Prevention and Treatment of Oral Mucositis and Dysgeusia in Patients Undergoing Radiotherapy lithium-containing mouthwash （Phase I）, Plcacebo mouthwash （Phase II）, lithium-containing mouthwash（Phase II） - Head and Neck Squamous Cell Carcinoma, Malignant Head and Neck Tumors | Phase 1 / Phase 2 | Completed | West China Hospital | 175 | 2024-03-01 | 2026-08-13 |
| EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma EBV-specific TCR-T cell with cytokine auto-secreting element - Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | Completed | Xinqiao Hospital of Chongqing | 9 | 2023-03-01 | 2026-01-20 |
| TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection, TQB2618 injection; Penpulimab injection - Nasopharyngeal Carcinoma | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 47 | 2022-10-27 | 2026-04-07 |
| Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). Bintrafusp alfa/M7824, Ibuprofen, PET scan - Olfactory Neuroblastoma, Esthesioneuroblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2022-06-21 | 2025-08-08 |
| Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy Streptococcus salivarius K12, Streptococcus salivarius K12 simulants - Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | West China Hospital | 160 | 2022-01-01 | 2024-02-05 |
| Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL) Toripalimab and Anlotinib - Nasopharyngeal Carcinoma, Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2 | Completed | Sun Yat-sen University | 40 | 2021-10-30 | 2024-12-12 |
| Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560 Fluorescein Sodium, YELLOW560 filter - Vestibular Schwannoma | Phase 2 | Completed | Mayo Clinic | 12 | 2021-10-06 | 2023-08-01 |
| A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Bintrafusp Alfa, PDS01ADC, Entinostat - Oropharyngeal Cancer, Neck Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2021-10-05 | 2026-09-22 |
| Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System tozuleristide, Canvas imaging system, Surgical resection of tumor - Central Nervous System Tumor | Phase 2 | Completed | John Yu | 50 | 2021-09-30 | 2026-07-10 |
| A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma TQB2450, Intensity modulated radiotherapy - Nasopharyngeal Carcinoma | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 25 | 2021-06-15 | 2024-09-26 |
| The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion, JS001 and JS004 - Head and Neck Squamous Cell Carcinom, Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | Completed | Shanghai Junshi Bioscience Co., Ltd. | 149 | 2021-05-11 | 2023-08-01 |
| Nedaplatin in Treatment for Nasopharyngeal Carcinoma Docetaxel, nedaplatin, fluorouracil, IMRT, Nedaplatin - Nasopharyngeal Carcinoma | Phase 2 | Completed | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 32 | 2021-05-01 | 2022-05-10 |
| Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC GP combine with Tislelizumab neoadjuvant therapy+CCRT - Nasopharyngeal Carcinoma | Phase 2 | Completed | Sun Yat-sen University | 63 | 2021-04-14 | 2025-07-08 |
| Evaluation of the Photobiomodulation Using LED Lamp for Curative Treatment of Radio-induced Mucositis. LED photobiomodulation - Oral Cancer, Oropharyngeal Cancer | Phase 2 | Completed | Centre Oscar Lambret | 28 | 2021-03-19 | 2026-03-18 |
| A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma AK105, Cisplatin, Gemcitabine - Nasopharyngeal Carcinoma | Phase 2 | Completed | Akeso | 28 | 2021-02-25 | 2025-03-07 |
| Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma Apatinib mesylate tablet, PD-1 - Nasopharyngeal Carcinoma | Phase 2 | Completed | Wei Jiang | 25 | 2021-01-14 | 2023-01-13 |
| Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin Cisplatin, Hearing Handicap Inventory for Adults - Screening, Radiation Therapy - Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Completed | Hyunseok Kang, MD | 16 | 2020-10-14 | 2024-06-28 |
| HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers PRGN-2009, M7824, EKG - HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 39 | 2020-08-11 | 2026-08-18 |
Showing 20 of 172. Sign in to see all of them.
Nasopharyngeal Carcinoma (65) · Oropharyngeal Neoplasms (46) · Head and Neck Neoplasms (42) · Nasopharyngeal Neoplasms (42) · Laryngeal Neoplasms (31) · Mouth Neoplasms (28) · Squamous Cell Carcinoma of Head and Neck (23) · Hypopharyngeal Neoplasms (20) · Neurofibromatosis 2 (13) · Neuroma, Acoustic (11) · Uterine Cervical Neoplasms (11) · Carcinoma, Squamous Cell (9) · Recurrence (9) · Tongue Neoplasms (9) · Salivary Gland Neoplasms (8)
Otorhinolaryngologic Diseases (171) · Neoplasms by Site (170) · Neoplasms (168) · Pharyngeal Diseases (144) · Stomatognathic Diseases (144) · Pharyngeal Neoplasms (139) · Head and Neck Neoplasms (114) · Neoplasms by Histologic Type (112) · Neoplasms, Glandular and Epithelial (100) · Nasopharyngeal Diseases (99) · Carcinoma (89) · Nasopharyngeal Neoplasms (57) · Respiratory Tract Diseases (36) · Respiratory Tract Neoplasms (35)
Cisplatin (36) · Fluorouracil (16) · Cetuximab (15) · Radiotherapy, Intensity-Modulated (15) · Radiotherapy (13) · Docetaxel (11) · Gemcitabine (8) · Carboplatin (7) · Paclitaxel (5) · Radiation (5) · pembrolizumab (5) · Bevacizumab (4) · Capecitabine (4) · Celecoxib (4) · Hydroxyurea (4)
National Cancer Institute (NCI) (15) · Sun Yat-sen University (15) · Memorial Sloan Kettering Cancer Center (5) · Fuda Cancer Hospital, Guangzhou (4) · University of Michigan Rogel Cancer Center (4) · Akeso (3) · NYU Langone Health (3) · Sanofi (3) · UNC Lineberger Comprehensive Cancer Center (3) · University of Alabama at Birmingham (3) · Affiliated Cancer Hospital & Institute of Guangzhou Medical University (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Chinese Academy of Medical Sciences (2) · Chinese University of Hong Kong (2) · Dana-Farber Cancer Institute (2)
United States (76) · China (61) · Canada (8) · France (8) · Hong Kong (8) · Singapore (6) · South Korea (4) · Taiwan (4) · Thailand (4) · United Kingdom (4) · Brazil (2) · Germany (2) · Indonesia (2) · Italy (2) · Malaysia (2)
Charalampos Floudas, M.D. (3) · Matthias A Karajannis, MD, MS (3) · Chen-ping Zhang, MD, PhD (2) · Chong Zhao (2) · Everett E. Vokes, MD (2) · Fu Zhao (2) · Iris Chan (2) · Jibing Chen, MD, PhD (2) · Li Gao, MD (2) · Li Zhang, MD (2) · Li Zhang, Master (2) · Pinan Liu (2) · Xiaozhong Chen, MD (2)
PMID 32017652, PMID 10811668, PMID 14520092, PMID 16597660, PMID 16750333, PMID 16823067, PMID 16849759, PMID 17545536, PMID 19525472, PMID 20439512, PMID 20447554, PMID 20830768, PMID 21246519, PMID 21358293, PMID 21831465, PMID 22252927, PMID 23083061, PMID 23341517, PMID 23639862, PMID 25142813, PMID 25229260, PMID 25407966, PMID 25498307, PMID 25702326, PMID 25823737, PMID 25965900, PMID 26062933, PMID 26084990, PMID 26186556, PMID 26581135, PMID 26611425, PMID 26976425, PMID 27567279, PMID 28222215, PMID 28498880, PMID 28712533, PMID 29346519, PMID 29526341, PMID 29584545, PMID 29602860, PMID 29764853, PMID 29885994, PMID 30412221, PMID 30689735, PMID 30714987, PMID 30850872, PMID 31150573, PMID 31411949, PMID 31705729, PMID 31785337
P30CA006973 (2), U10CA031946 (2), 2009 (1), 2014 (1), 2015 (1), 2018 (1), 2019 (1), N01CM00099 (1), N01CM62201 (1), P30CA006516 (1), P30CA015704 (1), P30CA023074 (1), P50CA096784 (1), P50CA097007 (1), R21CA130281 (1)